Journal
BLOOD
Volume 119, Issue 8, Pages 1901-1903Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2011-11-391748
Keywords
-
Categories
Funding
- Canadian Institutes of Health Research
- Canadian Cancer Society
- Terry Fox Foundation
- Leukemia & Lymphoma Society
- Institut National du Cancer
- Program Hospitalier de Recherche Clinique
- Fondation pour la Recherche Medicale
- Institut Universitaire de France
- CITTIL
- Cancer Plan research Program (Belgium)
- National Cancer Institute [5U01/CA114778]
- National Institutes of Health [U01/CA84967]
- lymphoma SPORE [P50CA13641-02]
- Eppley Core grant
Ask authors/readers for more resources
Mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) occur in most grade 2 and 3 gliomas, secondary glioblastomas, and a subset of acute myelogenous leukemias but have not been detected in other tumor types. The mutations occur at specific arginine residues and result in the acquisition of a novel enzymatic activity that converts 2-oxoglutarate to D-2-hydroxyglutarate. This study reports IDH1 and IDH2 genotyping results from a set of lymphomas, which included a large set of peripheral T-cell lymphomas. IDH2 mutations were identified in approximately 20% of angioimmunoblastic T-cell lymphomas (AITLs), but not in other peripheral T-cell lymphoma entities. These results were confirmed in an independent set of AITL patients, where the IDH2 mutation rate was approximately 45%. This is the second common genetic lesion identified in AITL after TET2 and extends the number of neoplastic diseases where IDH1 and IDH2 mutations may play a role. (Blood. 2012;119(8):1901-1903)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available